215 related articles for article (PubMed ID: 23586510)
1. Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
Shinoda T; Yamasaki M; Chida Y; Takagi M; Tanaka Y; Ando R; Suzuki T; Tagawa H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():29-34. PubMed ID: 23586510
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Ishizu T; Hong Z; Matsunaga T; Kaneko Y; Taru Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():22-8. PubMed ID: 23586509
[TBL] [Abstract][Full Text] [Related]
3. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
4. Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Takeuchi K; Matsuda E; Sekino M; Hasegawa Y; Kamo Y; Kikuchi N; Sekino H
Ther Apher Dial; 2013 Apr; 17 Suppl 1():15-21. PubMed ID: 23586508
[TBL] [Abstract][Full Text] [Related]
5. Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
Ota S; Hirose M; Izumiya Y; Ishida Y
Ther Apher Dial; 2013 Apr; 17 Suppl 1():49-53. PubMed ID: 23586513
[TBL] [Abstract][Full Text] [Related]
6. Study of prolonged administration of lanthanum carbonate in dialysis patients.
Gotoh J; Kukita K; Tsuchihashi S; Hattori M; Iida J; Horie T; Onodera K; Furui H; Tamaki T; Meguro J; Yonekawa M; Kawamura A
Ther Apher Dial; 2013 Apr; 17 Suppl 1():9-14. PubMed ID: 23586507
[TBL] [Abstract][Full Text] [Related]
7. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
8. Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
Hyodo T; Kawakami J; Mikami N; Wakai H; Ishii D; Yoshida K; Iwamura M; Hida M; Kurata Y
Ther Apher Dial; 2014 Jun; 18 Suppl 1():14-7. PubMed ID: 24953761
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
11. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Manabe R; Fukami K; Ando R; Sakai K; Kusumoto T; Hazama T; Adachi T; Kaida Y; Nakayama Y; Ueda S; Kohno K; Wada Y; Yamagishi S; Okuda S
Ther Apher Dial; 2013 Apr; 17 Suppl 1():35-40. PubMed ID: 23586511
[TBL] [Abstract][Full Text] [Related]
12. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Wei Y; Kong XL; Li WB; Wang ZS
Ther Apher Dial; 2014 Dec; 18(6):618-22. PubMed ID: 24674384
[TBL] [Abstract][Full Text] [Related]
14. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
15. Clinical experiences of bixalomer usage at our hospital.
Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
[TBL] [Abstract][Full Text] [Related]
16. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Sprague SM; Ross EA; Nath SD; Zhang P; Pratt RD; Krause R
Clin Nephrol; 2009 Oct; 72(4):252-8. PubMed ID: 19825330
[TBL] [Abstract][Full Text] [Related]
17. Lanthanum carbonate for hyperphosphatemia in patients on peritoneal dialysis.
Ohno M; Ohashi H; Oda H; Yokoyama H; Okada M; Nagaya M; Izumi K; Ito H; Katoh S
Perit Dial Int; 2013; 33(3):297-303. PubMed ID: 23209037
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
19. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
[TBL] [Abstract][Full Text] [Related]
20. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
